Business Context and Reporting Period
Company: Tempus AI, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Tempus AI is a healthcare technology company combining laboratory testing with artificial intelligence and machine learning to improve patient care. The company operates as a single segment, deriving revenue primarily from Genomics (laboratory testing) and Data and Services (licensing de-identified data and clinical trial support). The company is an emerging growth company and expects to become a large accelerated filer by December 31, 2025.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | As of Sept 30, 2025 |
|---|---|---|---|
| Total Net Revenue | $334.2 million | $904.6 million | N/A |
| Net Loss | $(80.0) million | $(190.9) million | N/A |
| Adjusted EBITDA | $1.5 million | $(20.3) million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $655.9 million |
| Total Debt (Long-term + Current) | N/A | N/A | $1.24 billion |
| Stockholders' Equity | N/A | N/A | $507.8 million |
Note: Total Debt includes Convertible Senior Notes ($726.9M), Long-term debt net ($200.9M), Revolving Credit Facility ($100.0M), and Convertible Promissory Note ($218.0M).
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 85% year-over-year for the quarter and 84% for the nine-month period.
- Genomics: Revenue surged 117% (Q3) and 108% (9M), driven by increased test volume and the acquisition of Ambry Genetics Corporation (Feb 2025), which added hereditary testing capabilities.
- Data and Services: Revenue grew 26% (Q3) and 34% (9M), primarily due to increased demand for Insights products and the Pathos Foundation Model agreement.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 85% in Q3 but decreased 19% for the nine-month period compared to 2024. The nine-month decrease was largely due to a $336.2 million reduction in stock-based compensation expenses related to RSU vesting conditions satisfied in the prior year's IPO.
- Acquisitions: Significant business combinations occurred in 2025, including Ambry Genetics ($692M consideration), Paige.AI ($103M), and Deep 6 AI ($17M), resulting in $391.7 million of new goodwill and substantial intangible assets.
- Debt Restructuring: The company issued $750 million in 0.75% Convertible Senior Notes due 2030 in July 2025. Proceeds were used to repay $276.9 million of the Term Loan Facility, resulting in a $12.0 million loss on debt extinguishment.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash, cash equivalents, and marketable securities ($660.5 million total) are sufficient to fund operations for at least 12 months.
- Capital Markets: The company entered an At-The-Market (ATM) sales agreement in August 2025, selling $195.5 million of stock in Q3 with approximately $300 million remaining available.
- Strategic Collaborations: A significant $200 million data license agreement with Pathos AI (related party) was signed in April 2025, with $50 million paid upfront.
- Risks and Contingencies:
- Legal Proceedings: Pending patent infringement litigation with Guardant Health Inc. regarding liquid biopsy technology. A federal securities class-action lawsuit (Shouse v. Tempus AI) is pending, which the company intends to defend vigorously.
- Regulatory: Ongoing government inquiries regarding billing and patient records (Ohio Attorney General, U.S. Attorney's Office for EDNY) related to Medicare/Medicaid compliance.
- Convertible Notes: Risks related to potential dilution upon conversion of the $750 million senior notes and the impact of the Capped Call transactions on stock price.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and revenue contributions from the Ambry Genetics, Paige.AI, and Deep 6 AI acquisitions, particularly regarding the $391.7 million in new goodwill.
- Reimbursement Rates: Monitor trends in Medicare and commercial payer reimbursement rates for Genomics tests, which drove a significant portion of recent revenue growth.
- Debt Covenants: Confirm continued compliance with Credit Agreement covenants, specifically the minimum consolidated revenue requirements ($1.0 billion trailing twelve months for 2025).
- Legal Exposure: Assess the potential financial impact of the Guardant Health patent litigation and the securities class-action lawsuit.
- Stock-Based Compensation: Review future stock-based compensation expenses, noting the significant one-time reduction in 2024 due to IPO-related vesting that skewed year-over-year comparisons.